Physician

Sharon Agnes Levandowski, MD

According to 2025 Medicare claims, Sharon Levandowski, MD (NPI: 1144244500) practices hematology/oncology in the Midland, MI market, with the plurality of this provider's patient population coming from Midland, MI. This provider's primary affiliated billing organization is MYMICHIGAN MEDICAL CENTER ALPENA (NPI: 1942302302; TIN: 386000029) and primary practice location at 48640-6128. Levandowski is affiliated with the POM ACO (ACO ID: A1297), Mosaic ACO (ACO ID: A5033), and Honest MSSP of Michigan LLC (ACO ID: A5616), participating under the MSSP model.

Levandowski's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 264 traditional Medicare patients, billed 1,154 HCPCS/CPT codes, and received $70,853 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 2,030 prescription claims across 373 beneficiaries totaling $3,843,000 in drug costs, led by Ibrance (Palbociclib). DME data shows 19 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing started with an early spike, then settled into a lower baseline, moving from $1,184,280 to $70,853. In contrast, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,354,246 to $3,843,000. For DME billing, this smaller-volume category started with an early spike, then settled into a lower baseline, moving from $20,112 to $3,060.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	447	85,390	$1,184,280
2016	505	125,658	$1,504,660
2017	422	1,416	$79,796
2018	449	1,440	$81,964
2019	471	1,376	$86,874
2020	438	1,074	$65,508
2021	377	702	$48,072
2022	215	436	$26,178
2023	180	372	$22,902
2024	264	1,154	$70,853

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	301	3,489	$1,354,246
2016	333	3,795	$1,691,695
2017	305	3,090	$1,459,895
2018	316	3,155	$1,961,658
2019	347	2,997	$2,490,213
2020	366	3,214	$3,732,018
2021	388	2,950	$3,452,697
2022	414	3,036	$4,216,213
2023	430	3,113	$5,984,348
2024	373	2,030	$3,843,000

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	155	$14,749
2016	N/R	130	$8,689
2017	N/R	126	$15,150
2018	N/R	14	$872
2019	N/R	48	$3,776
2020	N/R	71	$2,232
2021	N/R	16	$1,962
2022	N/R	27	$2,916
2023	N/R	39	$4,520
2024	N/R	19	$2,252

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	45	45	$140
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	148	222	$111
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	36	36	$87
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	202	331	$76
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	209	437	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	35	1,092	$624,492
Lenalidomide	Lenalidomide	36	1,008	$576,093
Calquence	Acalabrutinib Maleate	21	630	$294,960
Venclexta	Venetoclax	34	1,014	$234,138
Tagrisso	Osimertinib Mesylate	13	390	$202,401

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	19	$2,252

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Sharon Agnes Levandowski, MD?

Tedicare shows public-source Medicare data for Sharon Agnes Levandowski, MD (NPI 1144244500), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sharon Agnes Levandowski, MD have ACO affiliation data?

Sharon Agnes Levandowski, MD is shown with ACO affiliation data for POM ACO (MSSP, ACO ID A1297), Mosaic ACO (MSSP, ACO ID A5033), and Honest MSSP of Michigan LLC (MSSP, ACO ID A5616).

What billing organization is linked to Sharon Agnes Levandowski, MD?

Sharon Agnes Levandowski, MD is linked to MYMICHIGAN MEDICAL CENTER ALPENA (billing NPI 1942302302) in the available physician profile data.

Does Sharon Agnes Levandowski, MD have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.